Tanaka Masafumi, Hashiguchi Yojiro, Ueno Hideki, Hase Kazuo, Mochizuki Hidetaka
Department of Surgery I, National Defense Medical College, Tokorozawa, Japan.
Dis Colon Rectum. 2003 Aug;46(8):1054-9. doi: 10.1007/s10350-004-7280-z.
The aim of this study was to identify indicators that can predict patients at high risk of tumor recurrence in Stage II, T3 colon cancer.
A total of 138 patients classified as Stage II, T3 underwent curative resection of colon cancer between 1981 and 1993. Clinical variables included age, gender, bowel obstruction, tumor location, and emergency presentation. For each colon tumor specimen, the following histopathological variables were assessed: maximum tumor diameter (<5 vs. >or=5 cm), depth, tumor grade (well and moderate vs. other), lymphatic and venous invasion (absent vs. present), perineural invasion, tumor necrosis, and tumor margin (expanding vs. infiltrating). We also categorized tumor budding, defined as a single cancer cell or small clusters of undifferentiated cancer cells in the invasive frontal lesion, into two categories: none or minimal (BD-1), and moderate or severe (BD-2). Univariate analysis for factors regarding recurrence and disease-specific survival were performed with the logistic regression model and the log-rank test.
Among the factors analyzed, tumor budding was the only factor that was significantly associated with recurrence and survival. The numbers of patients with BD-1 and BD-2 tumors were 111 and 27, respectively. Forty-eight percent of BD-2 tumor patients developed recurrence, compared with 4.5 percent of BD-1 tumor patients (P < 0.0001). The cumulative disease-specific survival rates at five years for patients with BD-1 and BD-2 tumors were 98 and 74 percent, respectively (P < 0.0001).
The presence of moderate or severe budding at the invasive margin in Stage II, T3 colon cancer indicated a high risk of tumor recurrence after curative surgery, providing useful information for the decision regarding postoperative adjuvant chemotherapy.
本研究旨在确定可预测II期T3结肠癌患者肿瘤复发高风险的指标。
1981年至1993年间,共有138例被分类为II期T3的患者接受了结肠癌根治性切除术。临床变量包括年龄、性别、肠梗阻、肿瘤位置和急诊情况。对于每个结肠肿瘤标本,评估以下组织病理学变量:最大肿瘤直径(<5 cm与≥5 cm)、深度、肿瘤分级(高分化和中分化与其他)、淋巴管和静脉侵犯(无与有)、神经周围侵犯、肿瘤坏死和肿瘤边缘(膨胀性与浸润性)。我们还将肿瘤芽生(定义为浸润性前沿病变中的单个癌细胞或小簇未分化癌细胞)分为两类:无或极少(BD-1)和中度或重度(BD-2)。使用逻辑回归模型和对数秩检验对复发和疾病特异性生存相关因素进行单因素分析。
在分析的因素中,肿瘤芽生是唯一与复发和生存显著相关的因素。BD-1和BD-2肿瘤患者的数量分别为111例和27例。BD-2肿瘤患者中有48%发生复发,而BD-1肿瘤患者为4.5%(P<0.0001)。BD-1和BD-2肿瘤患者的五年累积疾病特异性生存率分别为98%和74%(P<0.0001)。
II期T3结肠癌浸润边缘存在中度或重度芽生表明根治性手术后肿瘤复发风险高,为术后辅助化疗决策提供了有用信息。